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Background: The African Programme for Onchocerciasis Control (APOC) has refocused its goals on the elimination
of infection where possible, seemingly achievable by 15–17 years of annual mass distribution of ivermectin in some
African foci. Previously, APOC had focused on the elimination of onchocerciasis as a public health problem.
Timeframes have been set by the World Health Organization, the London Declaration on Neglected Tropical
Diseases and the World Bank to achieve these goals by 2020–2025.
Methods: A novel mathematical model of the dynamics of onchocercal disease is presented which links documented
associations between Onchocerca volvulus infection and the prevalence and incidence of morbidity and mortality to
model outputs from our host age- and sex-structured onchocerciasis transmission framework (EpiOncho). The model is
calibrated for African savannah settings, and used to assess the impact of long-term annual mass administration of
ivermectin on infection and ocular and skin disease and to explore how this depends on epidemiological and
programmatic variables.
Results: Current onchocerciasis disease projections, which do not account for excess mortality of sighted individuals
with heavy microfilarial loads, underestimate disease burden. Long-term annual ivermectin treatment is highly effective
at reducing both the morbidity and mortality associated with onchocerciasis, and this result is not greatly influenced
by treatment coverage and compliance. By contrast, impact on microfilarial prevalence and intensity is highly
dependent on baseline endemicity, treatment coverage and systematic non-compliance.
Conclusions: The goals of eliminating morbidity and infection with ivermectin alone are distinctly influenced by
epidemiological and programmatic factors. Whilst the former goal is most certainly achievable, reaching the latter will
strongly depend on initial endemicity (the higher the endemicity, the greater the magnitude of inter-treatment
transmission), advising caution when generalising the applicability of successful elimination outcomes to other areas.
The proportion of systematic non-compliers will become far more influential in terms of overall success in achieving
elimination goals.
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Human onchocerciasis is also known as ‘river blindness’
because the simuliid vectors that transmit the infection
breed in fast flowing rivers, and because the embryonic
stages or microfilariae (mf) of the parasite Onchocerca
volvulus can enter the eye and cause irreversible visual
impairment and blindness [1]. This is a protracted and
chronic process because continual exposure to many in-
fective vector bites is needed to build up a substantial
worm burden and ensuing microfilarial infection (of skin
and ocular tissues), and because adult female worms
(which produce hundreds to thousands of mf daily) live,
on average, for ten years [2]. The adult stages (macrofi-
lariae) reside in worm bundles located subcutaneously
(palpable nodules) or deeply in the body, where they
produce the mf which migrate to the skin (microfilari-
dermia) and the eyes [3]. Immunological responses to
filarial products [4], either of parasite origin or their
endosymbiotic Wolbachia bacteria [5], lead to long-
standing, non-resolving inflammation associated with
chronic onchocerciasis pathology [6]. Skin pathology
ranges from troublesome itching to (disfiguring) skin
changes, including early-stage reactive lesions, and late-
stage depigmentation (leopard skin) and atrophy [7].
Moreover, individuals with high microfilaridermia suffer
an increased risk of death [8,9], independent of that re-
lated to blindness [10], i.e. sighted individuals are also
subject to an excess risk of death.
Currently the predominant strategy for onchocerciasis
control in Africa is annual community-directed treat-
ment with ivermectin (CDTI) to all those aged five years
and older (excluding pregnant or breastfeeding women
in the first week after delivery) [11,12]. Ivermectin is a
safe and potent microfilaricide, also temporarily redu-
cing the production of live mf by adult female worms
for some months after treatment (anti-fertility effect)
[13,14]. Spurred by success in some foci of Mali, Nigeria
and Senegal [15-17], there has recently been a shift in
onchocerciasis control policy in Africa, changing from
elimination of the public health burden of onchocer-
ciasis, to elimination of the infection. The African
Programme for Onchocerciasis Control (APOC) has a
new goal of eliminating onchocerciasis where possible
by 2025 [18], and the 2012 London Declaration on
Neglected Tropical Diseases (LDNTD) joined the World
Health Organization’s (WHO) 2020 Roadmap on NTDs
[19] and set goals for elimination of onchocerciasis in se-
lected countries of Africa by 2020 [20]. Rigorous evalu-
ation of the feasibility of achieving these targets, and of
the benefits already accrued necessitates the contribu-
tion of dynamic models of onchocerciasis infection and
disease.
In this paper, a mathematical model of the dynamics of
onchocercal disease is developed by linking documentedassociations between infection, morbidity and mortality to
output from our onchocerciasis transmission model
(EpiOncho) [14,21-24]. We assess the long-term impact of
annual mass drug administration (MDA) of ivermectin on
disease and infection in different epidemiological and pro-
grammatic settings in savannah areas of Africa. Note-
worthy novel features of EpiOncho, overlooked in other
modelling studies [25,26], include: (a) a direct association
between the intensity of infection with O. volvulus mf and
excess human mortality [8,9], which was not included in
recent estimates of the global burden of onchocerciasis
[27], and (b) due consideration of uncertainty in the long-
term antifilarial effects of repeated treatments with iver-
mectin [23].
The stochastic microsimulation ONCHOSIM model
has been used to assess the health impact of APOC (as a
whole) [26] and the hypothetical feasibility of onchocer-
ciasis elimination in different settings [28]. Based on
Plaisier et al. [29], ONCHOSIM projections have as-
sumed that ivermecitn has a large cumulative impact on
female adult worm fertility (a large anti-macrofilarial ac-
tion). However, several studies have indicated that this
may not be the case [30,31]. Consequently, ivermectin’s
long-term impact may currently be overestimated [23].
Finally, there is an increased recognition of the need to
inform control programmes with more than one model-
ling approach in order to enhance the potential of mod-
elling for decision making in public health [32].
Methods
Onchocerciasis transmission model
The analysis is underpinned by a deterministic oncho-
cerciasis transmission model (EpiOncho) which de-
scribes sex-specific rates of change with respect to time
and host age in the mean number of fertile and non-
fertile female adult worms per host, the mean number of
mf per milligram (mg) of skin, and the mean number of
L3 larvae per fly. The model has been refined from the
original framework developed by Basáñez and Boussinesq
[21], to include age and sex structure of the host popula-
tion (in particular, age- and sex-dependent exposure to
blackfly bites, parameterized using intensity data on
microfilaridermia) [22]; the population-level effects of a
single [14,24] and multiple [23] treatments with iver-
mectin, and increased programmatic realism related to
patterns of treatment coverage and systematic non-
compliance (whose effects can be explored separately)
[23]. The assumed human age- and sex-structure of the
population reflects demographic characteristics in savannah
areas of northern Cameroon [22,33,34], where the prevail-
ing O. volvulus–Simulium damnosum sensu lato (s.l.)
combinations (i.e. savannah parasites–S. damnosum sensu
stricto (s. str.)/S. sirbanum) are responsible for the most
severe sequelae of onchocerciasis [1,3]. We assumed a
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tion. The model can reflect pre-control infection levels in
a range of hypo- (>35% microfilarial prevalence), meso-
(35–60% microfilarial prevalence), and hyperendemic
(>60% microfilarial prevalence) onchocerciasis foci [35] by
varying the annual biting rate (ABR) of the simuliid vec-
tors (Table 1).
Ivermectin effects
The model has been modified to incorporate the tem-
poral dynamics of the microfilaricidal and anti-fertility
(embryostatic) effects of ivermectin [14,24] (Table 2). Al-
though the initial clinical trial studies that investigated
the effects of a single standard dose (150 μg/kg) of iver-
mectin have shown no evidence of a macrofilaricidal ac-
tion [38,39], multiple doses of ivermectin over several
years may have a cumulative adverse effect on the fertility
and/or longevity of adult worms [17,29,40-42]. To ac-
count for this potential anti-macrofilarial effect of long-
term ivermectin MDA, it was assumed that each dose of
ivermectin causes a 7% cumulative reduction in the per
capita rate of microfilarial production by adult female
worms.
This value was motivated by matching EpiOncho’s
model output (via varying the per dose reduction) to
data on microfilarial load after three years of three-
monthly ivermectin treatments (over twelve treatments
rounds) presented in Gardon et al. [43].
These authors estimated the magnitude and statistical
significance of the ivermectin effect on female worm fer-
tility to be greater than on worm mortality; therefore, we
chose the former to represent a cumulative, per dose,
anti-macrofilarial action of the drug [43]. Despite the
higher treatment frequency examined (three-monthly),
this dataset was chosen to assess the per dose anti-
macrofilarial action of ivermectin, because of the num-
ber of treatment rounds the participants were exposed
to (over twelve treatment rounds) and because the mi-
crofilarial load was presented per mg of skin and not per
skin snip (allowing for accurate comparison to EpiOncho’s
output).Table 1 Summary of baseline (pre-control) modelled epidemi
Pre-control endemicity Annual biting
rate (ABR)§†
Annual
transmission
potential (ATP)¶†
Microfilar
prevalen
in all ag
Mesoendemic 7,300 88 40%
Hyperendemic 15,470 373 60%
Highly hyperendemic 85,800 4,290 80%
§Modelled annual biting rate (ABR): the average number of (S. damnosum s.str./S. si
¶Modelled annual transmission potential (ATP): the average number of infective larv
exposed to the annual biting rate; model assumes perennial transmission.
†Both the ABR and ATP are for a proportion of vector blood meals of human origin
‡Nodule prevalence (recorded by APOC) is converted to microfilarial load in this ag
*Arithmetic mean microfilarial load per mg of skin; note that this is different to the
load per skin snip in those aged 20 years and above) [37].There is a lack of well-characterized long-term (indi-
vidual) longitudinal data (including previous treatment
history) to estimate more accurately the potential anti-
macrofilarial action of ivermectin [23]. The estimated
per dose reduction of 7% is consistent with data from re-
cent epidemiological evaluations conducted in areas of
Cameroon that have received 13 years of ivermectin dis-
tribution. These data do not support the operation of a
strong cumulative effect of repeated treatments on the
microfilarial production of female worms [31]. In
addition, a modelling study by Bottomley et al. [30], in-
dicated that ivermectin did not seem to have a cumula-
tive effect on microfilarial production after two and a
half years of six-monthly treatments [44]. However, a
relatively small reduction would have had a minor initial
impact, and thus may not have been detectable in this
short time frame.
Our estimated, per ivermectin dose, reduction in the
rate of microfilarial production by female worms is
smaller than the 30–35% irreversible reduction proposed
by Plaisier et al. [29], and which these authors estimated
by fitting a model to data on five consecutive annual
treatments presented in [45], and used in ONCHOSIM
[25,26,28]. Therefore, we varied the strength of this anti-
macrofilarial action of ivermectin in our sensitivity
analysis.
Estimates of disease burden
An onchocerciasis disease model was developed by link-
ing output from our dynamic transmission model to the
prevalence and incidence of onchocerciasis-associated
morbidity and mortality (Figure 1). A summary of how
each disease state was represented is found below. Full
mathematical details are provided in Additional file 1:
Text S1 and Additional file 1: Figures S1-S3. Table S1
summarises the definition and values of parameters and
variables for the onchocerciasis disease model.
Vision loss
The number of people blind due to onchocerciasis (de-
fined as corrected visual acuity of <3/60 or restriction ofological scenarios
ial
ce
es
Microfilarial
prevalence in those
aged ≥ 5 years‡
Mean microfilarial
intensity* in all
ages (mf/mg)
Mean microfilarial
intensity* in those
≥ 20 yr (mf/mg)
47% 11.2 18.7
67% 23.9 40.0
84% 58.9 98.0
rbanum) bites to which a person is exposed during a whole year.
ae (L3) of O. volvulus potentially received during a whole year by a person
equal to 0.3 [21].
e range [36].
community microfilarial load (CMFL), which is the geometric mean microfilarial
Table 2 Effects of ivermectin on various parasite stages
Parameters Definition
Microfilaricidal effect The increase in microfilarial mortality.
Anti-fertility effect The temporary reduction in the production of live microfilariae by adult female worms (also known as embryostatic effect).
Anti-macrofilarial effect The long-term, cumulative adverse effect on adult worms due to prolonged exposure of the parasites to the drug
(represented in the model as a per dose reduction in the per capita rate of microfilarial production by adult female worms).
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calculated by means of a partial differential equation
comprising two rates: the incidence of new onchocercal-
related blindness cases, and the loss of already blind in-
dividuals due to (excess) mortality [10,48] (see section
Excess Mortality). The former incidence rate was esti-
mated based on a log-linear Poisson model developed by
Little et al. [46], which describes incidence of blindness
as a function of microfilarial load lagged by two years
(fitted to the cohort dataset of the Onchocerciasis Con-
trol Programme in West Africa, OCP). The two-year lag
provided, which was the best fit to the data [46], reflects
that loss of visual acuity is associated with past microfi-
larial load. Consequently, the decline in prevalence of vi-
sion loss was also lagged by two years after the start of
ivermectin distribution. The number of individuals with
visual impairment or low vision (defined as corrected
visual acuity of <18/60 and ≥3/60 in the better eye [47])
caused by onchocerciasis was estimated using a pub-
lished ratio of 1.78 visual impairment to blindness [47].
Prevalent blindness and visual impairment cases were
assumed to be irreversible conditions unresponsive to
ivermectin treatment [49], which does not reverse estab-
lished ocular sequelae (also including sclerosing keratitis
and optic nerve atrophy).
Troublesome itch
Troublesome itch is thought to be associated with the
presence of infection [50] but not with microfilarial infec-
tion intensity [51,52]. Hence, we applied a relationshipFigure 1 Schematic representation of the disease model. Prevalence o
prevalence of adult female worms, previously derived using the ONCHOSIM
microfilarial load (lagged by two years) based on a log-linear Poisson mode
using a published ratio between the prevalence of visual impairment and t
assumed to occur via mortality among individuals suffering onchocerciasis-
independent (from the former) risk of mortality among sighted individuals wi
are provided in the main text and Additional file 1: Text S1.between the prevalence of troublesome itch and of adult
female worms, previously derived using ONCHOSIM
[25,26]. Troublesome itch was related to the presence of
female adult worms because the association between the
presence of mf and troublesome itch does not hold during
ivermectin treatment, the reduction in prevalence of itch
being smaller and more delayed than the drop in microfi-
larial prevalence and load [25,26,53]. This relationship is
subject to considerable uncertainty and so it was varied in
the sensitivity analysis (Table 3). In addition, we parame-
terised the empirical therapeutic effect of ivermectin on
troublesome itch using results from a multi-centre trial of
ivermectin for treating onchocercal skin disease and se-
vere itching [53] as described in Additional file 1: Text S1.
Consequently, there is an initial sharp decline in the
prevalence of troublesome itch (as a result of ivermectin’s
therapeutic effect) followed by a more gradual decrease as
the prevalence of adult worms declines, with a delay
driven by the assumed two year pre-patent period [22,54].
Excess mortality
Excess mortality due to onchocerciasis was assumed to
occur via two independent processes: (a) an additional
risk of mortality among individuals suffering onchocercal
related vision loss [10,48], and (b) an additional risk of
mortality among (sighted) individuals with high microfi-
larial loads [8,9]. The former (a) was modelled using a risk
of mortality among blind and visually impaired individuals
that is, respectively, 2.5 and 1.5 times higher than that of
fully sighted individuals [48]. The latter (b) was modelledf troublesome itch was estimated based on a relationship with the
model [25,26]. Incidence of blindness was estimated as a function of
l [46]. The number of individuals with visual impairment was estimated
hat of blindness [47]. Excess mortality due to onchocerciasis was
related vision loss (blindness and visual impairment) [10,48], plus an
th high microfilarial load (lagged by two years) [8,9]. Further descriptions
Table 3 Definitions and values of the parameters explored in the sensitivity analysis
Parameters Values
Initial endemicity: pre-control (baseline) microfilarial prevalence in the
overall population (all ages), as percentage
40% (mesoendemic), 60% (hyperendemic), 80% (highly hyperendemic)
Therapeutic coverage: overall proportion of the total population receiving
ivermectin at each round, as percentage
60% (moderate) and 80% (high)
Proportion of systematic non-compliers: fraction of the eligible
population who never take treatment, as percentage
0.1% (lower) and 5% (higher) treatment adherence
Anti-macrofilarial action of ivermectin: per dose, cumulative reduction in
microfilarial production by ivermectin-exposed female adult worms
[23,29], as percentage
7% (small) and 30% (large) anti-macrofilarial effect
Relationship between infection and troublesome itch: nonlinear regression
coefficient of the association between prevalence of adult female worms
and that of troublesome itch [26] (see also eqn. S.16 of Additional file 1)
α2 ± 25% (stronger or weaker association between prevalence of
female worms and prevalence of troublesome itch
Turner et al. Parasites & Vectors 2014, 7:241 Page 5 of 15
http://www.parasitesandvectors.com/content/7/1/241using a published non-linear, host age-dependent associ-
ation between the relative risk of mortality of sighted indi-
viduals and their microfilarial load (lagged by two years)
estimated from the OCP cohort dataset [9].
Disability-adjusted life years
Disability-adjusted life years (DALYs) due to onchocer-
ciasis were used to combine into a single metric the bur-
den of blindness, visual impairment, troublesome itching
(years lived with disability, YLD), and premature death
(years of life lost, YLL). The DALYs were estimated using
the disability weights provided by the Global Burden of
Disease (2004) study [55] (see Additional file 1: Text S2).
The YLLs were discounted at a rate of 3% per year, in
agreement with WHO guidelines [56]. Further descrip-
tion of the DALY calculations is provided in Additional
file 1: Text S2 and Additional file 2: Table S2.
Model outputs and sensitivity analysis
We estimated the pre-control disease burden associated
with onchocerciasis in African savannah areas within the
range of endemicities explored (Tables 1 and 3). In
addition, the model was used to estimate the overall mi-
crofilarial prevalence (all ages) and intensity (reported as
the mean microfilarial load per mg of skin in those aged
≥20 years), as this is the age range used for assessmentTable 4 Baseline (pre-control) model-derived burden of disea
areas of Africa at different levels of endemicity
Disability Adjusted
Years of life with disability (YLD)
Pre-control endemicity‡ Blindness
(ratio)*
Visual impairment
(ratio)*
Troub
itch (
Mesoendemic 3.6 1.4 7
Hyperendemic 11.4 (3.2) 4.4 (3.1) 15.3
Highly hyperendemic 49.0 (13.6) 18.8 (13.4) 21.0
§See Additional file 1: Text S2 for a detailed description of the methods used to cal
†In line with WHO guidelines, a discount rate of 3% was applied to YLLs [56].
*Ratio of metric with respect to the value for the mesoendemic level.
‡ Pre-control microfilarial prevalence as in Table 1.of community microfilarial load (CMFL) [37]) and its as-
sociated morbidity and mortality over the course of 15
annual ivermectin treatment rounds. We chose 15 years
because (a) it is a reasonable duration for modelling the
long-term impact of ivermectin treatment and making
comparisons between different scenarios, and (b) epi-
demiological studies have documented apparent elimin-
ation in this approximate timescale [15-17].
The sensitivity of model projections was explored with
regards to a range of epidemiological (endemicity setting)
and treatment effectiveness (programmatic variables and
treatment efficacy) assumptions. Table 3 presents the defi-
nitions and values of the parameters that were explored in
the sensitivity analysis.
Results
Pre-control disease burden
Before the inception of mass ivermectin distribution and
in the absence of other control interventions, infection
by O. volvulus in African savannah areas can be associ-
ated with a large burden of disease, which is non-linearly
related to baseline endemicity. This is illustrated by the
pre-control (total) DALY burden stratified by baseline
endemicity in Table 4 and Figure 2. Relative to the bur-
den for the mesoendemic level (represented by a micro-
filarial prevalence of 40%), the burden corresponding tose (DALYs) associated with onchocerciasis in savannah
Life Years (DALYs)§ (per 1000 person-years)
Years of life lost (YLL)†
lesome
ratio)*
Associated with
vision loss
(ratio)*
Associated with
high microfilarial
load (ratio)*
Total DALY
burden (ratio)*
.0 2.7 5.9 20.6
(2.2) 8.8 (3.3) 29.6 (5.0) 69.5 (3.4)
(3.0) 37.0 (13.7) 72.3 (12.3) 198.7 (9.6)
culate DALYs.
Figure 2 Relationship between the level of endemicity and pre-
control disease burden associated with onchocerciasis in
savannah areas of Africa. Total disability adjusted life-years (DALY)
associated with onchocerciasis (black); years of life with disability
(YLD) associated with onchocerciasis-related blindness (dark blue);
YLD associated with onchocerciasis-related visual impairment (red);
YLD associated with onchocerciasis-related troublesome itch (green);
years of life lost (YLL) associated with vision loss (light blue); YLL
associated with high microfilarial load (purple).
Figure 3 Impact of annual ivermectin distribution on the morbidity a
(a) Prevalence of blindness due to onchocerciasis (across all ages). (b) Prev
(c) Prevalence of troublesome itch due to onchocerciasis (across all ages). R
endemicity of 80%, 60% and 40% microfilarial prevalence. Results shown assu
perennial transmission, and a 7% cumulative reduction in microfilarial produc
the intervention at year 1 is represented by the vertical dashed lines. Delays in
lag between vision loss in the present and microfilarial infection in the past. T
therapeutic effect of ivermectin followed by a more gradual decrease as adul
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the highly hyperendemic level (80% microfilarial preva-
lence at baseline), is seven times as high. In terms of the
specific pre-control burdens of morbidity and mortality,
onchocerciasis was associated with: (a) high levels of
blindness and visual impairment, with the baseline over-
all prevalence (across all ages) of onchocercal related
blindness reaching over 8% in highly hyperendemic areas
(Figures 3a and 3b); (b) high levels of troublesome itch
(Figure 3c), with the estimated pre-control overall preva-
lence reaching over 30% in highly hyperendemic areas,
and (c) a substantial incidence of excess mortality
(Table 4 and Figure 2). The YLLs associated with high
microfilarial load were responsible for a substantially
higher proportion of excess host mortality than those as-
sociated with onchocercal related vision loss (Table 4
and Figure 2).
Impact of ivermectin on microfilarial prevalence and
intensity
Long-term (15 years of consecutive) annual ivermectin
distribution is projected to reduce progressively and
markedly (by more than 90%), the intensity of microfi-
larial infection (measured in the population aged ≥20
years). However, due to the dynamic nature of ivermec-
tin’s action on the production of mf by adult female
worms, these parasite stages reappear in the skin (withssociated with onchocerciasis in savannah areas of Africa.
alence of visual impairment due to onchocerciasis (across all ages).
ed, blue and green lines correspond, respectively, to a baseline
me a therapeutic coverage of 80%, 0.1% of systematic non-compliance,
tion by female adult worms per ivermectin dose. The commencement of
the decrease of blindness and visual impairment are due to a two-year
he initial sharp decline in troublesome itch is due to the assumed
t worm prevalence declines.
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consecutive annual treatments (Figure 4a). The degree
of skin repopulation by mf is strongly related to pre-
control endemicity (reflecting adult worm burden and
vector density) and is substantially larger for (highly)
hyperendemic areas. The impact on microfilarial preva-
lence (all ages) is less marked (yet larger than approxi-
mately an 80% reduction) than that on microfilarial
intensity (due to the nature of the non-linear relation-
ship between these two variables, Additional file 1:
Figure S1) and decreases with increasing levels of pre-
control endemicity (Figure 4b).
Impact of ivermectin on Onchocerciasis disease burden
Morbidity
Model outputs indicate that long-term annual distribu-
tion of ivermectin has an enormous impact on the mor-
bidity associated with onchocerciasis (Figure 3). Two
years after the start of ivermectin distribution, the inci-
dence of blindness (associated with lagged microfilarial
load) is projected to fall to very low levels (Figure 5). By
contrast, the proportion of individuals with blindness
and visual impairment due to onchocerciasis declines
more gradually, as prevalent cases are slowly removed
due to host mortality, but not replaced at the same pre-
control incidence level. There is a very strong initial de-
cline in the prevalence of troublesome itch due to the
therapeutic benefit of ivermectin on cutaneous patholo-
gies [53], followed by a more steady decline during the
programme due to a gradual reduction in transmission
(and prevalence of adult female worms), the magnitudeFigure 4 Impact of annual ivermectin distribution on the intensity (a)
lines correspond, respectively, to a baseline endemicity of 80%, 60% and 40
mean microfilarial load per mg of skin in those aged≥ 20 years. The dashe
prevalence) of the current operational thresholds for cessation of treatmen
surveyed villages and 1% in 90% of the surveyed villages [57]. Assumptions
microfilarial infection intensity (in the ≥ 20 yr of age) for the last four yearsof which depends on pre-control endemicity level (the
higher the level the lower the rate of decrease). However,
there is considerable uncertainty regarding the impact of
ivermectin on troublesome itching (Additional file 1:
Figure S4).
Excess mortality
Under ivermectin distribution the incidence of excess
mortality associated with high microfilarial load is pro-
jected to decrease rapidly to low levels (Figure 6a). The
decline is delayed by two years after the start of ivermec-
tin distribution because the incidence of excess mortality
due to infection is associated with microfilarial load ex-
perienced two years in the past [8]. The incidence of ex-
cess mortality associated with onchocercal related vision
loss decreases at a slower rate, following the decline in
the prevalence of vision loss (Figure 6b).
Disability-adjusted life years
The overall impact (on morbidity and mortality) of iver-
mectin distribution on the DALY disease burden associ-
ated with onchocerciasis is illustrated in Additional file 1:
Figure S5.
Impact of programmatic variables: therapeutic coverage
and compliance patterns
Varying the level of therapeutic coverage and the pro-
portion of systematic non-compliers influences the pro-
jected impact of long-term ivermectin distribution on
microfilarial prevalence and intensity. An increased level
of overall therapeutic coverage (from 60% to 80%), or anand prevalence (b) of microfilarial infection. Red, blue and green
% microfilarial prevalence. Microfilarial intensity is quantified as the
d horizontal lines illustrate the upper and lower bounds (5% and 1%
t, namely an observed microfilarial prevalence below 5% in all
are as in legend of Figure 3. The inset in Figure 4 (a) zooms in
of the simulated intervention programme.
Figure 5 Impact of annual ivermectin distribution on incidence
of blindness due to onchocerciasis in savannah areas of Africa.
Red, blue and green lines correspond to, respectively, a baseline
endemicity of 80%, 60% and 40% microfilarial prevalence. The
commencement of the intervention at year 1 is represented by the
vertical dashed line. The initially delayed decrease is due to a two-
year lag between blindness incidence in the present and microfilarial
load in the past. Results shown assume a therapeutic coverage of
80%, 0.1% of systematic non-compliance, perennial transmission, and
a 7% cumulative reduction in microfilarial production by female
adult worms per ivermectin dose.
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portion of systematic non-compliers, from 5% to 0.1%)
decreases microfilarial prevalence and intensity mea-
sured 1 year after the 15th annual treatment (Tables 5
and 6). The proportional reduction in infection due to
improved coverage or compliance is generally greater forFigure 6 Impact of annual ivermectin distribution on the excess mort
(a) Associated with a high microfilarial load. (b) Associated with vision loss
onchocerciasis. Red, blue and green lines correspond, respectively, to a bas
Assumptions are as in Figure 3. The commencement of the intervention at
decrease of excess mortality is due to a two-year lag between incidence othe meso- and hyperendemic levels than for the highly
hyperendemic level. By contrast, the proportional re-
ductions in onchocerciasis-associated disease burden
resulting from improved coverage and compliance were
relatively small in comparison.
Impact of the efficacy of ivermectin anti-macrofilarial action
The magnitude of the assumed anti-macrofilarial effect
of ivermectin (i.e. the per dose proportion by which mi-
crofilarial production by female worms is cumulatively
reduced) influenced the long-term impact of annual iver-
mectin distribution on microfilarial prevalence and in-
tensity. The higher value (30%, as assumed in ONCHOSIM
[25,26,28]) had a more pronounced effect than the lower
(7%) value (Additional file 1: Figure S6 in comparison to
Figure 4). However, this effect also depended on the base-
line level of onchocerciasis endemicity; the lower the pre-
control endemicity, the smaller the impact of assuming
the stronger anti-macrofilarial effect (Additional file 2:
Table S3). By contrast, the magnitude of the anti-
macrofilarial effect had little influence on the impact of
annual ivermectin MDA on onchocerciasis-associated dis-
ease burden (Additional file 2: Table S3).
Discussion
The influence of the epidemiological setting
Pre-control disease burden
In the absence of control interventions, onchocerciasis
poses a high disease burden which is non-linearly related
to pre-control endemicity level. Model outputs of base-
line prevalence of onchocercal related vision loss andality associated with onchocerciasis in savannah areas of Africa.
(blindness/visual impairment). (c) Total excess death associated with
eline endemicity of 80%, 60% and 40% microfilarial prevalence.
year 1 is represented by the vertical dashed lines. The initially delayed
f death in the present and microfilarial load in the past.
Table 5 The effect of annual ivermectin treatment coverage on the microfilarial prevalence and intensity of onchocerciasis
infection and its associated morbidity and mortality according to baseline endemicity
Pre-control endemicity‡ Mesoendemic Hyperendemic Highly hyperendemic
Therapeutic coverage 60% 80% %† change 60% 80% %† change 60% 80% %† change
Skin microfilarial prevalence§ (%) 3.46 1.84 47% 9.52 4.74 50% 27.53 16.69 39%
Microfilarial intensity§ (mf/mg) 1.08 0.49 55% 3.1 1.31 58% 11.14 5.47 51%
Blindness prevalence§ (%) 0.299 0.297 0.67% 0.95 0.91 4% 4.25 4.13 3%
Visual impairment prevalence§ (%) 0.4015 0.4014 0.02% 1.27 1.22 4% 5.7 5.54 3%
Troublesome itch prevalence§ (%) 2.79 1.80 36% 9.43 3.73 32% 17.38 14.09 19%
Excess mortality annual incidence§ (per 1000) 0.09 0.08 11% 0.29 0.26 10% 1.39 1.13 19%
§Values correspond to model outputs 12 months after the 15th annual ivermectin treatment assuming perennial transmission, 0.1% of systematic non-compliance
(high treatment adherence) and a 7% cumulative, per ivermectin dose, reduction in the rate of microfilarial production by adult female worms. Microfilarial
infection intensity is quantified as arithmetic mean microfilarial load per mg of skin in those aged ≥ 20 years.
†Proportional (percent) reduction in parasitological, morbidity and mortality indicators relative to the lower (60%) treatment coverage of the total population
(overall therapeutic coverage).
‡ Pre-control microfilarial prevalence as in Table 1.
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consistent with published data [50,58-60]. Our estimated
blindness rates are in good agreement with those re-
ported prior to the commencement of interventions in
the core area of the former OCP [58-60]. However, there
is heterogeneity in reports of (observed) prevalence of
onchocerciasis-associated morbidity, particularly regard-
ing the prevalence of troublesome itch (Additional file 1:
Figure S4) [50,58-60].
The estimated DALYs include the excess mortality of
sighted individuals with heavy microfilarial loads [8,9],
which has not been considered elsewhere. At baseline,
the contribution of this mortality associated with infec-
tion was greater than the mortality associated with
vision loss, and the difference between these two com-
ponents of premature death increased with increasing
levels of pre-control endemicity. This suggests that pre-
mature death related to onchocerciasis, and conse-
quently its overall contribution to disease burden mayTable 6 The effect of the proportion of systematic non-complia
prevalence and intensity of onchocerciasis infection and its ass
endemicity
Pre-control endemicity‡ Mesoendemic
Systematic non-compliance 5% 0.1% %† cha
Skin microfilarial prevalence§ (%) 2.6 1.84 29%
Microfilarial intensity§ (mf/mg) 0.8 0.49 39%
Blindness prevalence§ (%) 0.299 0.297 1%
Visual impairment prevalence§ (%) 0.41 0.4 2%
Troublesome itch prevalence§ (%) 2.22 1.80 19%
Excess mortality annual incidence§ (per 1000) 0.09 0.08 11%
§Values correspond to model outputs 12 months after the 15th annual ivermectin t
80% (high coverage), and a 7% cumulative, per ivermectin dose, reduction in the ra
intensity is quantified as arithmetic mean microfilarial load per mg of skin in those
†Proportional (percent) reduction in parasitological, morbidity and mortality indicat
treatment adherence).
‡ Pre-control microfilarial prevalence as in Table 1.be higher than previously estimated [25-27,48]. Recent
estimates of the global disease burden of onchocerciasis
[27], which did not include excess host mortality, are
therefore underestimated.
Impact of ivermectin on microfilarial prevalence and intensity
The impact of long-term annual ivermectin distribution
on onchocerciasis prevalence and intensity decreases
with increasing levels of baseline (pre-control) endem-
icity, consistent with other modelling studies [28,57,61].
Although our projections indicate that prolonged annual
ivermectin distribution reduces substantially the ocular
morbidity and excess mortality associated with oncho-
cerciasis, partly due to very large reductions in microfi-
larial infection intensity, its impact on the prevalence of
infection (and arguably on transmission) is less pro-
nounced. (This will be the product of a combined effect
of the non-linear relationship between microfilarial
prevalence and intensity, and the relaxation of thence with annual ivermectin treatment on the microfilarial
ociated morbidity and mortality according to baseline
Hyperendemic Highly hyperendemic
nge 5% 0.1% %† change 5% 0.1% %† change
6.68 4.74 29% 20.08 16.69 17%
2.2 1.31 40% 8.18 5.47 33%
0.95 0.91 4% 4.26 4.13 3%
1.27 1.22 4% 5.7 5.54 3%
7.66 3.73 16% 14.95 14.09 6%
0.3 0.26 13% 1.29 1.13 12%
reatment assuming perennial transmission, an overall treatment coverage of
te of microfilarial production by adult female worms. Microfilarial infection
aged ≥ 20 years.
ors relative to the higher (5%) proportion of systematic non-compliance (lower
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ment and vector survival incorporated in the model
[62].) This finding is in accordance with the conclusions
of a review assessing the impact of repeated ivermectin
MDA in the former OCP area [63] and highlights that
although the onchocercal disease burden will be mark-
edly reduced, and likely eliminated as a public health
problem, continued drug distribution at high levels of
treatment coverage and compliance will be vital to inter-
rupt transmission and eliminate the infection reservoir.
After 15 years of annual ivermectin MDA, with con-
sistently high therapeutic coverage, compliance and drug
efficacy, projected values of microfilarial prevalence in
mesoendemic (1.8%) and hyperendemic (4.7%) areas
(Figure 4b, Table 5), approach the operational thresholds
for treatment interruption followed by surveillance
(OTTIS) proposed by APOC [57]. (These thresholds are
defined by a prevalence less than 5% in all surveyed vil-
lages and less than 1% in 90% of these and <0.5 infective
larvae per 1,000 flies.) Hence, our results are consistent
with epidemiological observations in Mali, Senegal and
Nigeria after 15–17 years of ivermectin distribution [15-17].
Projected reductions in microfilarial prevalence and
intensity were less optimistic for higher levels of the
hyperendemicity range (80% initial microfilarial preva-
lence). In such settings there would be a higher rate of
microfilarial reappearance in the skin between consecu-
tive treatments (as adult female worms resume microfi-
larial production and transmission continues with high
vector densities in the absence of vector control). Al-
though under repeated and prolonged ivermectin treat-
ment this rebound in microfilarial intensity was found
not to have severe implications for morbidity, it will
make it harder to achieve the proposed OTTIS, so our
results advise caution when generalising conclusions re-
garding the feasibility of parasite elimination with annual
ivermectin treatment to areas of high pre-control en-
demicity and perennial transmission.
The shift in onchocerciasis control policy in Africa,
from the elimination of morbidity to the elimination of
infection [18], means that the dynamics of transmission
during inter-treatment periods is increasingly relevant,
highlighting the value of mathematical models in captur-
ing the population dynamic effects of underlying bio-
logical and epidemiological processes. In particular, our
results indicate that if ivermectin does not have a strong
anti-macrofilarial action (a strong action has been as-
sumed in ONCHOSIM [25,26,28]), elimination in highly
hyperendemic areas is not feasible with annual ivermec-
tin MDA alone. This conclusion is supported by a range
of recent epidemiological reports by Katabarwa and co-
workers which provide evidence of continued transmis-
sion after more than 15 years of annual ivermectin
treatment in foci of Cameroon and Uganda with highpre-control endemicity or transmission levels [64-66].
Our model projections, combined with these epidemio-
logical observations, underscore the importance of de-
veloping novel interventions and implementing optimal
combinations of currently available tools [67].
Impact of ivermectin on Onchocerciasis disease burden
Prolonged annual ivermectin distribution is undoubtedly
highly effective at reducing the morbidity and excess
mortality associated with onchocerciasis. Our projec-
tions of a steady decline in the prevalence of blindness,
agree with studies investigating the long-term impact of
onchocerciasis control on vision loss as well as with
ONCHOSIM projections [26,59,60,68,69]. However, our
projected reduction in onchocercal related vision loss
was less than that reported by Emukah et al. [70], who
observed a fall in prevalence from 16% to 1% (a 95% re-
duction) after only eight years of annual ivermectin dis-
tribution. This difference could be explained by a higher
incidence of excess mortality experienced by individuals
with vision loss in the study area [70] than assumed in
our model. Others have assumed that four rounds of
ivermectin treatment would reduce the burden of visual
impairment and blindness by 35% [71]. In our model
there is no therapeutic benefit of ivermectin on (irre-
versible) vision loss; therefore, reductions in prevalence
are due to gradual mortality of those with blindness/vis-
ual impairment. This contrasts with the faster reduction
in the incidence of blindness, which reaches very low
levels within a few years of ivermectin MDA (due to its
pronounced effect on microfilarial load). However,
onchocerciasis-related vision loss may still account for a
non-negligible disease burden during on-going control
programmes due to remaining prevalent cases. The con-
tribution of prevalent blindness cases was not included
in recent estimates of the global burden of onchocercal
disease [27].
Model outputs indicating that the overall prevalence
of troublesome itch due to onchocerciasis would roughly
halve after 5–6 years of annual ivermectin treatment are
consistent with data from a multi-centre trial assessing
the impact of CDTI on itching and skin disease within
APOC [72]. This study consisted of two cross-sectional
surveys using a standardised study protocol across seven
sites. Other authors have assumed that four rounds of
ivermectin treatment would reduce the prevalence of
troublesome itching by 85% [71], but this optimistic ex-
pectation is not supported by the results of [72] or our
modelling outputs. With the exception of two studies by
Whitworth et al. [73,74], which concluded that ivermec-
tin had no effect on skin disease, our projected reduc-
tions are in broad agreement with the literature
[53,72,75-77]. Subsequent studies by Whitworth et al.
using a longer time period and an improved study
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after six years of annual ivermectin treatment [76]. It
should be noted that after 15 years of ivermectin treat-
ment in mesoendemic areas, our projections indicate a
small (1.8%) residual prevalence of troublesome itch.
This is associated with a substantial degree of uncer-
tainty due to limitations of available data and a lack of
long-term longitudinal data to parameterise accurately a
potential cumulative reduction in itching prevalence.
The influence of programmatic and drug efficacy variables
Therapeutic coverage and compliance patterns
Varying levels of overall coverage (comparing a moder-
ate therapeutic coverage of the total population of 60%
with a higher coverage of 80%), and levels of systematic
non-compliance (comparing a low treatment adherence,
with 5% of individuals never taking treatment with a
high compliance of only 0.1%) had little effect on the
substantial impact that regular and prolonged ivermectin
treatment has on the morbidity and excess mortality as-
sociated with onchocerciasis. However, both these pro-
grammatic considerations had a marked influence on
the projected impact of annual ivermectin treatment on
the prevalence and intensity of microfilarial infection
[23]. This indicates that under the new impetus for elim-
ination of infection (as opposed to elimination of mor-
bidity only) [18], the proportion of the population that
for whatever reason always refuse treatment, cannot take
it, or cannot be reached will become very important in
terms of achieving parasite elimination goals. Oper-
ational research efforts should be made to understand
what proportion of the population (stratified by age and
sex) do not take treatment [78,79], what are the reasons
behind this non-compliance, and how to develop effect-
ive strategies to increase treatment adherence [23]. In
addition, it will also be important to ascertain whether
and to what extent systematic non-compliers are repre-
sented in monitoring and evaluation sampling protocols;
it is conceivable that individuals who are non-compliant
to treatment may not be present during parasitological
assessments, biasing results and potentially leading to er-
roneous decisions concerning cessation of treatment.
Anti-macrofilarial effect of ivermectin
Based on [30,31,43], it was assumed that ivermectin would
only have a relatively small anti-macrofilarial action, i.e.,
effecting a 7% cumulative reduction on the rate of microfi-
larial production by adult female worms per standard
dose. Due to uncertainty in the magnitude of this effect
[23], analyses were also conducted assuming the operation
of a stronger (30% per dose) anti-macrofilarial action (as
previously assumed in ONCHOSIM [25,26,28]) [29].
Varying this parameter had a prominent impact on pro-
jected microfilarial prevalence and intensity, but did notgreatly affect the projected impact on disease burden. The
degree to which the magnitude of the anti-macrofilarial ef-
fect influenced infection levels decreased with decreasing
pre-control endemicity, reflecting the lower degree of re-
sidual transmission occurring between consecutive treat-
ments [23].
Potential limitations
Currently, our transmission and disease EpiOncho model
has been calibrated for savannah settings of Africa; thus,
results are not necessarily directly generalisable to forest
settings which have different relationships between infec-
tion and sequelae [1,3], different transmission intensities
[80], and where onchocerciasis vectors are different mem-
bers of the Simulium damnosum s.l. complex [81] (but
also see [82] for a review of blindness associated with dif-
ferent epidemiological and entomological settings in
savannah and forest areas).
The present version of the model assumes a stationary
age distribution and a stable (closed) population and
consequently does not account for potential effects of
onchocerciasis-related excess host mortality on the
population distribution. Additionally, the results pre-
sented here assume that transmission is perennial (i.e.
occurs all year round). Further investigation of the influ-
ence of different seasonal transmission patterns on the
optimal timing of ivermectin distribution will be essen-
tial and is underway.
As in other modelling studies of the health impact of
ivermectin [26], we included disease manifestations for
which data were available for model parameterisation.
However, we have not yet quantified disease burden as-
sociated with other types of skin disease (such as leopard
skin among others) [50,72], and therefore we may be
underestimating the pre-control disease burden and the
overall health impact of ivermectin. Furthermore, oncho-
cerciasis is associated with epilepsy [83,84], nodding dis-
ease, and Nakalanga syndrome [85,86], which have not yet
been included in disease models. It is clear that further
work and data are required to improve assessment of the
disease burden associated with onchocerciasis in future it-
erations of the Global Burden of Disease study.
EpiOncho is a deterministic model and does not ac-
count for the influence of random events (which become
particularly important at low infection levels). Therefore,
it cannot be used to investigate formally the probability of
reaching elimination, which requires a stochastic model.
Finally, it is noteworthy that most models (including
ours) are parameterised with data collected prior to the
onset of control interventions, and it is possible that the
relationships between infection, transmission and the sub-
sequent development of morbidity could be influenced by
the treatment per se [87]. Consequently, any model-
derived predictions of the long-term impact of ivermectin
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ease burden (particularly regarding troublesome inching)
are somewhat uncertain.
Programmatic considerations
Onchocerciasis control programmes based on annual
ivermectin distribution have been in operation in Africa
for a considerable time (since 1988 and early 1990’s in
some countries of the OCP, and since 1995 to late 1990’s
in countries under the umbrella of APOC). Our results
confirm those of other authors [26,63] in concluding
that this strategy is highly effective in controlling
onchocerciasis-related morbidity and reducing dramatic-
ally the incidence of new cases of ocular disease. Our
work also reveals, for the first time, that the incidence of
excess host mortality associated with heavy microfilarial
infection (in sighted individuals) would also plummet
after some initial lag. It is, therefore, highly likely that
the goals of eliminating the public health burden of on-
chocerciasis will be met within the timeframes agreed by
the international global health community, drug donors,
project funders and control programmes. The rates at
which morbidity in general, and each disease state in
particular, decline in the human population will depend
on the epidemiological setting, the initial intensity of in-
fection and transmission, and to a much lesser extent on
programmatic variables (although only two, moderate
and high, values of therapeutic coverage were investi-
gated here). It is anticipated that much lower levels of
therapeutic coverage, poor geographical coverage or
interruption of programmes due to conflict, population
displacement or weak programme implementation among
other factors, would be detrimental to the reaching of
morbidity elimination goals. A stumbling block here is the
existence of areas coendemic for Loa loa infection
[88], in which ivermectin treatment may be contraindi-
cated in those with very high loiasis microfilaraemia
because of the risk of severe adverse events [89]. This
represents a big threat to the possibility of ridding
Africa of onchocerciasis.
The influence of epidemiological and programmatic
factors is very different regarding the feasibility of
achieving infection elimination goals, and here we need
to give a more cautionary appraisal. This goal will prob-
ably be achievable in mesoendemic, and possibly in the
lower end of the hyperendemic spectrum (provided high
treatment effectiveness is sustained). However, even
under enthusiastic scenarios of uninterrupted annual
ivermectin treatment, unwaveringly high therapeutic
coverage/compliance, and intact drug efficacy, settings
with initially very high infection prevalence will challenge
the programmes in their attempt to reach interruption of
transmission with annual ivermectin distribution alone.
This indicates that (highly) hyperendemic settings willrequire implementation of innovative approaches or
optimised combination of existing ones; for instance,
implementation of biannual ivermectin treatment to re-
duce the amount of remaining transmission between
consecutive treatment rounds [90], concomitant vector
control where possible [91], and treatment (on a test &
treat basis) with macrofilaricidal therapies such as
doxycycline, proven to sterilise permanently female
parasites and kill adult worms [92].
Furthermore, it must be borne in mind that at
present, proposed operational thresholds for tentative
cessation of treatment (and initiation of post-control
surveillance) are, by and large, empirical, based on the
very stages most affected by treatment (and therefore
not truly representative of the fate of the parasite popu-
lation), and prone to decreased sensitivity of current
diagnostics. Their relationship with transmission break-
points (parasite densities below which the worm popu-
lation would not be able to maintain itself ) is largely
unknown [61].
Conclusions
The excess mortality of sighted individuals with heavy
microfilarial loads [8,9], which has not been considered
elsewhere, contributes to a considerable number of years
of life lost in onchocerciasis endemic populations. Con-
sequently, the overall disease burden of onchocerciasis
and ivermectin’s impact on health have thus far been
underestimated [25-27,48].
Long-term annual ivermectin treatment is highly ef-
fective in reducing the morbidity and excess mortality
associated with onchocerciasis. Consequently, the goals
of eliminating the public health burden of onchocerciasis
will most likely be met in those areas where long-term,
annual ivermectin distribution is feasible. However, due
to the dynamic nature of ivermectin’s action on the pro-
duction of microfilariae [14], these parasite stages will
reappear in the skin between consecutive annual treat-
ments; the degree of microfilarial repopulation is sub-
stantially larger in (highly) hyperendemic areas, making
the infection much harder to eliminate. This highlights
the importance of carefully considering the characteris-
tics of the settings in which epidemiological and model-
ling studies are conducted before generalising their
results to other areas. In particular, our results indicate
that caution is advised when generalising the conclusion
of the feasibility of elimination (observed in [15-17])
with annual treatment to areas with a higher pre-control
endemicity and perennial transmission, and further high-
lights the need for continued evaluation of the criteria
proposed for stopping ivermectin treatment (recognised
in [15,16]). This has important implications for both the
WHO’s and APOC’s goals to eliminate onchocerciasis in
selected countries of Africa by 2020/2025 [18,20].
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treatment coverage and level of systematic non-compliance
to ivermectin had little effect on the substantial impact
that long-term ivermectin has on onchocerciasis disease
burden. However, both variables had marked effects re-
garding reductions in infection prevalence and intensity.
This indicates that, now that the aim is elimination of the
infection where possible (instead of only reducing disease
burden), the proportion of systematic non-compliers (as
well as the overall coverage) will become far more influen-
tial in terms of overall success in achieving elimination
goals. This highlights the need for further investigation
and assessment of the determinants of treatment compli-
ance and indicates that feasibility of achieving the new
goals will depend on epidemiological and programmatic
variables, precluding a one-size-fits-all approach to on-
chocerciasis elimination in Africa.
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